Cogent Biosciences, Inc.COGTNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+238.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+238.7%/yr
Quarterly compound
Percentile
P95
Near historical high
vs 3Y Ago
38.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 66.60% |
| Q3 2025 | 7.38% |
| Q2 2025 | 12.39% |
| Q1 2025 | 1.84% |
| Q4 2024 | -0.94% |
| Q3 2024 | 16.91% |
| Q2 2024 | 4.06% |
| Q1 2024 | 2.00% |
| Q4 2023 | 0.59% |
| Q3 2023 | 15.08% |
| Q2 2023 | 14.10% |
| Q1 2023 | 2.80% |
| Q4 2022 | 1.71% |
| Q3 2022 | 7.98% |
| Q2 2022 | 7.20% |
| Q1 2022 | 16.04% |
| Q4 2021 | 2.09% |
| Q3 2021 | 2.39% |
| Q2 2021 | 6.91% |
| Q1 2021 | -14.23% |
| Q4 2020 | -4.47% |
| Q3 2020 | 99.79% |
| Q2 2020 | -23.73% |
| Q1 2020 | 36.38% |
| Q4 2019 | -0.99% |
| Q3 2019 | -11.14% |
| Q2 2019 | 22.92% |
| Q1 2019 | 21.87% |
| Q4 2018 | -13.65% |
| Q3 2018 | 19.61% |
| Q2 2018 | 86.00% |
| Q1 2018 | -26.16% |
| Q4 2017 | 8.84% |
| Q3 2017 | 36.35% |
| Q2 2017 | 2.86% |
| Q1 2017 | 0.00% |
| Q3 2016 | 0.00% |
| Q3 2015 | 0.00% |